Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.

Inclusion Criteria:

• Patients satisfying the Rome II Diagnostic Criteria.
• Patients in whom no organic changes were observed in large intestine.

Exclusion Criteria:

• Patients have diseases which interfere with evaluation of the efficacy and safety in this study.
• Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.